GlassScriptPhysician profile
James S Pope
NPI 1558318808
$124,697.96
in general payments reported to CMS, 2019-2025
33 companies · $67K in 2025
The $67K reported for 2025 was more than what 98% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $876 · 2020: $253 · 2021: $1,142 · 2022: $1,637 · 2023: $4,519 · 2024: $49K · 2025: $67K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $99K · Food and Beverage: $10K · Consulting Fee: $6,975 · Travel and Lodging: $4,096 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $99,446.50 |
| Food and Beverage | $10,094.11 |
| Consulting Fee | $6,975.00 |
| Travel and Lodging | $4,095.91 |
| Education | $178.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $111,375.46 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Mylan Specialty L.P. | $6,168.21 | 2019-2024 | Yupelri, Tobi Podhaler |
| Glaxosmithkline, LLC. | $3,296.99 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Amgen INC. | $634.09 | 2021-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $516.46 | 2019-2025 | Ofev, Jascayd |
| Mallinckrodt Hospital Products INC. | $435.72 | 2023-2025 | Acthar, Terlivaz |
| Regeneron Healthcare Solutions, INC. | $361.58 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $290.64 | 2023-2025 | Glassia |
| Verona Pharma, INC. | $253.16 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $221.27 | 2025 | Yupelri, Tobi Podhaler |
| Abbvie INC. | $137.02 | 2020-2025 | |
| Insmed, INC. | $133.49 | 2019-2025 | Arikayce |
| Jazz Pharmaceuticals INC. | $113.17 | 2019-2025 | |
| Electromed, INC. | $110.08 | 2024-2025 | Smartvest |
| Novartis Pharmaceuticals Corporation | $91.57 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $63.71 | 2019 | |
| Harmony Biosciences LLC | $57.33 | 2023 | Wakix |
| Circassia INC. | $49.58 | 2019 | |
| Pfizer INC. | $47.90 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $46.18 | 2024-2025 | Ultomiris |
| Allergan, INC. | $36.22 | 2019-2020 | |
| Advanced Respiratory, INC | $33.94 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $29.72 | 2024 | Lumryz |
| Janssen Pharmaceuticals, INC | $24.31 | 2019 | |
| Grifols USA, LLC | $23.79 | 2023 | Prolastin-C Liquid |
| Baxter Healthcare | $22.02 | 2024 | |
| Axsome Therapeutics, INC. | $21.25 | 2025 | Sunosi |
| Genentech USA, INC. | $21.07 | 2019 | |
| Paratek Pharmaceuticals, INC. | $18.65 | 2025 | Nuzyra |
| La Jolla Pharmaceutical Company | $17.92 | 2019 | |
| Merck Sharp & Dohme LLC | $17.32 | 2019 | |
| Genzyme Corporation | $14.51 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Pope listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.